IBRX
IBRX clinical trials: ImmunityBio, Inc.
Every trial on ClinicalTrials.gov where ImmunityBio, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 92
- Trials linked
- 83
- As lead sponsor
- 9
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IBRX on the catalyst calendar · IBRX registry changes
- Primary completion May 12, 2028Sponsor estimatePhase 2NCT07783789NAI Plus Standard of Care Compared To SOC Alone Plus Standard of Care in Critically Ill Adults With SepsisImmunityBio, Inc. · SepsisNot yet recruitingIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 3, 2027Sponsor estimatePhase 2NCT07578558NAI for Sepsis With Persistent LymphopeniaImmunityBio, Inc. · SepsisWithdrawnIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2028Sponsor estimatePhase 3NCT06745908Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in...ImmunityBio, Inc. · NSCLC Stage IVRecruitingIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2, 2026ActualPhase 1NCT04898543QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid TumorsImmunityBio, Inc. · Metastatic Solid TumorActive, not recruitingIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2025ActualPhase 2NCT04390399Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced...ImmunityBio, Inc. · Pancreatic CancerActive, not recruitingIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 1NCT07217496N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerImmunityBio, Inc. · Metastatic Urothelial CarcinomaNot yet recruitingIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 2NCT07123727A Study to Examine Anktiva for the Treatment of COVID-19.ImmunityBio, Inc. · Long COVIDRecruitingIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2, 2027Sponsor estimatePhase 1NCT05976828IBRX-042 In Participants With HPV-Associated TumorsImmunityBio, Inc. · HPV-Related CarcinomaActive, not recruitingIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2027Sponsor estimatePhase 1NCT07488884Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With...ImmunityBio, Inc. · Pancreatic Cancer ResectableWithdrawnIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2026ActualPhase 1NCT07556757A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic LeukemiaImmunityBio, Inc. · B-ALLTerminatedIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2027Sponsor estimatePhase 1NCT06334991Study for Participants With Relapsed/Refractory Non-Hodgkin LymphomaImmunityBio, Inc. · Non-Hodgkin Lymphoma Refractory/ RelapsedActive, not recruitingIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 2NCT06710288A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With...ImmunityBio, Inc. · Platinum-resistant Ovarian CancerRecruitingIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2029Sponsor estimatePhase 2NCT06061809N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaImmunityBio, Inc. · GlioblastomaActive, not recruitingIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 15, 2029Sponsor estimatePhase 3NCT07524257Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLCImmunityBio, Inc. · NSCLC (Advanced Non-small Cell Lung Cancer)WithdrawnIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2030Sponsor estimatePhase 2NCT07628062Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared...ImmunityBio, Inc. · HPV-Positive Oropharyngeal Squamous Cell CarcinomaNot yet recruitingIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2025ActualPhase 3NCT03520686Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerImmunityBio, Inc. · Non Small Cell Lung CancerTerminatedIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2032Sponsor estimatePhase 3NCT07551544ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder CancerImmunityBio, Inc. · NMIBCWithdrawnIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06810141ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder CancerImmunityBio, Inc. · NMIBCAvailableIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2026Sponsor estimatePhase 2NCT07108036A Study to Assess Anktiva in Patients With Long Covid-19.ImmunityBio, Inc. · Long COVIDRecruitingIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2026Sponsor estimatePhase 2NCT07492888Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)ImmunityBio, Inc. · Acute Respiratory Distress SyndromeWithdrawnIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 15, 2029Sponsor estimatePhase 3NCT07492875Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired PneumoniaImmunityBio, Inc. · Community-Acquired Pneumonia (CAP)WithdrawnIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2031Sponsor estimatePhase 2NCT06765954Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.ImmunityBio, Inc. · High-risk Prostate CancerWithdrawnIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2031Sponsor estimatePhase 2NCT06765902Immunotherapy Before and After SurgeryImmunityBio, Inc. · High-risk Prostate CancerWithdrawnIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 25, 2027Sponsor estimatePhase 2NCT07125872Study of Relapsed/ Refractory B-cell Non- Hodgkin LymphomaImmunityBio, Inc. · Relapsed B-Cell Non Hodgkin LymphomaRecruitingIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2033Sponsor estimateNo phase registeredNCT05981131Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)ImmunityBio, Inc. · Non Muscle Invasive Bladder CancerActive, not recruitingIBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 67 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner